Targeted Therapy Doubles Survival in BRAF V600E–Colorectal Cancer

作者
Dibash Kumar Das
出处
期刊:Oncology times [Wolters Kluwer]
卷期号:47 (11): 20-20
标识
DOI:10.1097/01.cot.0000000000000196
摘要

First-line treatment with encorafenib, cetuximab, and mFOLFOX6 significantly improved survival outcomes in patients with BRAF V600E–mutant metastatic colorectal cancer (mCRC), according to phase III data from the BREAKWATER trial published in The New England Journal of Medicine (2025; doi.org/10.1056/NEJMoa2501912). BRAF V600E mutations are present in approximately 8% to 12% of metastatic colorectal cancers, and are associated with a distinctly aggressive clinical phenotype. These tumors exhibit poor responses to standard chemotherapy and a markedly worse prognosis than their BRAF wild-type counterparts. Historically, median overall survival (OS) for patients with BRAF-mutated mCRC has hovered around 11 months with chemotherapy, compared to 24 months for those with wild-type disease. While the combination of encorafenib and cetuximab demonstrated efficacy in previously treated patients through the BEACON CRC trial, data supporting first-line use of BRAF- and EGFR-targeted therapy remained limited prior to BREAKWATER. The rationale for combining these targeted agents with chemotherapy emerged from mechanistic insights showing that monotherapy with BRAF inhibitors triggers EGFR-mediated pathway reactivation in CRC, blunting treatment responses. BREAKWATER was a global, open-label, phase III trial enrolling 637 adults with previously untreated, BRAF V600E–mutated mCRC. Participants were randomized to receive: encorafenib plus cetuximab (EC); EC combined with mFOLFOX6 chemotherapy (EC+mFOLFOX6); or standard investigator-selected chemotherapy (mFOLFOX6, CAPOX, or FOLFOXIRI) with or without bevacizumab. Following a protocol amendment, the EC-only arm was closed to focus analyses on EC+mFOLFOX6 vs. standard care. The two primary endpoints were objective response and progression-free survival (PFS) assessed by blinded central review. OS was a key secondary endpoint. Patients were stratified by ECOG performance status and geographic region. Efficacy Outcomes EC+mFOLFOX6 significantly improved median PFS to 12.8 months (95% CI: 11.2-15.9), compared with 7.1 months (95% CI: 6.8-8.5) for standard care (HR: 0.53; 95% CI: 0.41-0.68; P<0.001). Kaplan-Meier curves showed early and sustained separation favoring the triplet regimen. An updated interim analysis revealed a doubling in median OS with EC+mFOLFOX6 (30.3 months; 95% CI: 21.7-not estimable) vs. standard care (15.1 months; 95% CI: 13.7-17.7) (HR: 0.49; 95% CI: 0.38-0.63; P<0.001). Estimated 2-year survival rates were 52% with EC+mFOLFOX6 and 29% with standard care. Confirmed objective response rates were 65.7% with EC+mFOLFOX6 compared to 37.4% with standard care. Median time to response was just 7 weeks in both arms, but the duration of response was longer in the EC+mFOLFOX6 group (13.9 vs. 10.8 months). Subgroup analyses consistently favored EC+mFOLFOX6 across age groups, sex, tumor sidedness, and extent of metastases. While EC+mFOLFOX6 was associated with higher rates of grade ≥3 adverse events (81.5%) compared to standard care (66.8%), the toxicities were largely manageable with dose adjustments and supportive care. Common high-grade events included neutropenia (19%), anemia (15.1%), and neuropathy (6.9%). Serious adverse events occurred in 46.1% of EC+mFOLFOX6 recipients vs. 38.9% with standard care. Permanent discontinuation of any agent occurred in 26.7% and 17.5% of patients, respectively. Despite the intensity of the triplet regimen, the safety profile was consistent with expectations for the component agents. EC+mFOLFOX6's risk-benefit profile was considered favorable given its survival advantage. To gain additional insights into the study, Oncology Times spoke with senior author Scott Kopetz, MD, PhD, FACP, of The University of Texas MD Anderson Cancer Center, where he serves as Professor and Deputy Chair of GI Medical Oncology, Medical Director of TRACTION within the Division of Therapeutics Discovery, and Associate Vice President for Translational Integration. Oncology Times: How do you interpret the clinical significance of these findings, particularly the doubling of median overall survival? Kopetz: “The findings from BREAKWATER represent a new standard of care for patients with newly diagnosed metastatic colorectal cancer that is microsatellite stable (MSS) and with a BRAF V600E mutation. This is based on a doubling of median overall survival for EC+FOLFOX patients, compared to standard of care therapy (which included the option for cytotoxic doublets or triplets with or without bevacizumab and treatment with BRAF targeted therapy at second line and beyond).” Oncology Times: From your clinical experience, how manageable are the toxicities, and what strategies would you use to optimize tolerability in practice? Kopetz: “The overall rate of treatment emergent side effects varies by the duration of therapy, and EC+FOLFOX patients had a median PFS of 12.8 vs. 7.1 months in the SOC arm, with grade 3 or higher adverse event rate (without regard to attribution) of 81.5% vs. 66.8%, respectively. Importantly, the serious adverse events attributed to treatment was 19% for EC+FOLFOX compared to 21% for the standard of care arm. Side effects related to EC include acneiform rash, arthralgia, and anemia, which were rarely high grade and can be managed conservatively. Preventative strategies for rash management can follow that done for EGFR inhibitor combinations, and arthralgias commonly can be adequately treated with over-the-counter anti-inflammatory agents without requiring dose interruptions or reductions.” Oncology Times: Benefits were consistent across subgroups, even high-risk patients. How might this affect your first-line therapy choice? Kopetz: “The subgroup analysis demonstrates that this activity is present in all evaluated subsets, and would be considered a new standard of care for all patients with newly diagnosed mCRC with MSS tumors with BRAF V600E mutation. For patients who are not candidates for FOLFOX therapy (for example, due to pre-existing neuropathy or recent adjuvant therapy with oxaliplatin-containing regimen), a subsequent cohort of EC+FOLFIRI vs. SOC will be reported out later in the year. For the MSI-High population with BRAF V600E, we anticipate reporting results from the SEAMARK study of pembrolizumab with or without encorafenib and cetuximab in the near future.” Dibash Kumar Das is a contributing writer.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
昏睡的衬衫完成签到,获得积分10
1秒前
黑子完成签到,获得积分10
1秒前
聪明依柔完成签到 ,获得积分10
2秒前
3秒前
candiceli发布了新的文献求助20
3秒前
专注寻菱发布了新的文献求助10
3秒前
宋紫馨完成签到 ,获得积分10
4秒前
ali8ba完成签到,获得积分10
4秒前
三岁放火烧山完成签到,获得积分10
4秒前
dyy123完成签到,获得积分10
5秒前
Fayth完成签到,获得积分0
5秒前
江边拔草完成签到,获得积分10
5秒前
七安发布了新的文献求助10
5秒前
学术智子发布了新的文献求助10
6秒前
李健的小迷弟的应助被Sweetx采纳,获得10
7秒前
7秒前
awang发布了新的文献求助20
8秒前
Tong完成签到,获得积分10
8秒前
8秒前
如意听安完成签到,获得积分10
8秒前
领导范儿的应助被再睡亿分钟采纳,获得10
9秒前
9秒前
10秒前
mmol完成签到,获得积分10
10秒前
huang完成签到,获得积分10
11秒前
xixi发布了新的文献求助10
11秒前
七安完成签到,获得积分20
12秒前
赘婿的应助被dyy123采纳,获得10
12秒前
12秒前
12秒前
yy发布了新的文献求助10
12秒前
大模型的应助被zzh采纳,获得10
12秒前
John_Xiong完成签到,获得积分10
13秒前
华圣拿下巨蜥完成签到,获得积分10
13秒前
13秒前
13秒前
无花果的应助被远方采纳,获得10
13秒前
13秒前
ws发布了新的文献求助10
13秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182102
求助须知:如何正确求助?哪些是违规求助? 9571775
关于积分的说明 21819723
捐赠科研通 7778500
什么是DOI,文献DOI怎么找? 3433617
关于科研通互助平台的介绍 2557786
邀请新用户注册赠送积分活动 2479651